Thermo Fisher ScientificRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Thermo Fisher Scientific (TMO) reported revenue of $11.99B in Q2 2026, with Service its largest revenue segment at 43%.
Thermo Fisher ScientificLife-science tools group whose Patheon pharma services arm runs what the company calls the largest sterile fill-finish CDMO network. Acquired Sanofi's Ridgefield, NJ sterile fill-finish site in September 2025 and is investing about $1B across 60 CDMO sites in 2026, adding prefilled syringe, cartridge, and autoinjector assembly lines.
Q3 2024-Q2 2026
Q3 2024-Q2 2026
Q3 2024-Q2 2026
Thermo Fisher Scientific (TMO) is a Medical - Diagnostics & Research company. Life-science tools group whose Patheon pharma services arm runs what the company calls the largest sterile fill-finish CDMO network. Acquired Sanofi's Ridgefield, NJ sterile fill-finish site in September 2025 and is investing about $1B across 60 CDMO sites in 2026, adding prefilled syringe, cartridge, and autoinjector assembly lines. It was founded in 1956, is headquartered in Waltham, MA and employs about 125,000 people.
As of 2026-Q1, Thermo Fisher Scientific's revenue breaks down across Service (43%), Consumables (43%), Instruments (14%). See the revenue-by-segment chart for the full mix.
Track Thermo Fisher Scientific's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups Thermo Fisher Scientific in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Thermo Fisher Scientific, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.